Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Net Cash Flow (2016 - 2025)

Conmed (CNMD) has disclosed Net Cash Flow for 16 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 115.75% year-over-year to $1.9 million, compared with a TTM value of $13.9 million through Dec 2025, up 382.42%, and an annual FY2025 reading of $13.9 million, up 382.42% over the prior year.
  • Net Cash Flow was $1.9 million for Q4 2025 at Conmed, down from $5.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $29.6 million in Q2 2022 and bottomed at -$18.5 million in Q3 2022.
  • Average Net Cash Flow over 5 years is $793650.0, with a median of $1.6 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 4875.58% in 2021, while the deepest fall reached 2238.06% in 2021.
  • Year by year, Net Cash Flow stood at -$10.2 million in 2021, then skyrocketed by 37.2% to -$6.4 million in 2022, then dropped by 12.89% to -$7.2 million in 2023, then crashed by 62.91% to -$11.8 million in 2024, then soared by 115.75% to $1.9 million in 2025.
  • Business Quant data shows Net Cash Flow for CNMD at $1.9 million in Q4 2025, $5.0 million in Q3 2025, and -$3.1 million in Q2 2025.